Kura Oncology UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you, everyone, for joining us. My name is David Dai. I am a biotech analyst here at UBS. Welcome to the inaugural UBS conference here in London. It is our great pleasure to have Kura Oncology. We have the full team here with us. We have Jennifer Fulk, the new Chief Financial Officer, who is joining us here. Then we have Mollie Leoni, the Chief Medical Officer. Then we have Brian Powl, Chief Commercial Officer. So, we have the full team here on the panel. Then we are diving into some of the interesting stuff they are working on here. Given the fact that Kura, just for some background, for any investors here who are new to the story, Kura is a very interesting commercial stage company that has a menin inhibitor called ziftomenib, or KOMZIFTI, which treats relapsed/refractory AML.
They have been on the market since the beginning of this year, actually later toward the end of last year. So, it has been about three quarters. Most recently, the third quarter numbers look pretty compelling, especially given the quarter-over-quarter growth so far. Today, we will dive into that, some of the conversation there in terms of their commercial launch. At the same time, there is also other pipeline programs for KOMZIFTI in frontline AML. Outside of that, there is also a quite interesting farnesyl transferase inhibitor called darlifarnib that is in multiple different tumor types, including salivary gland cancer, which you are planning to do a registration trial for full approval soon. So, Molly will spend some time talking about that as well. So, great discussion here, and let us just dive into that real quick.
So, maybe for the audience in this space, just give us a quick overview of the Kura story here. There are some key commercial and pipeline programs you guys are working on here.
First of all, David, thank you for having us. As you mentioned, Kura Oncology is now a fully integrated company. We have got capabilities across research, development, and commercialization. We are working on two products that have the potential to be multi-billion dollar commercial drugs. First is ziftomenib, as you said, our menin inhibitor. The commercial name is KOMZIFTI. We announced last week our third full quarter results. As you mentioned, we are delighted with growth across the KPIs, so new patient starts, prescriptions, net revenue. Everything is green there. We are really excited by that. In addition, we believe that the future of improving patient outcomes is really moving towards the earlier lines of therapy and in combination.
We also talked about, and Molly will share more, that at ASH, we will have data importantly in FLT3 mutations, which FLT3 mutations occur in about a third of AML patients in total and half of NPM1 mutated patients. At the same time, we have our ongoing phase III trials, so in first line, in both intensive chemotherapy and non-intensive, so with Ven-Aza. We anticipate the initial top line results to be in 2028. We also have darlifarnib, it is our FTI program. Importantly, last week, we announced alignment with the FDA for a 40-patient registrational trial in HRAS mutant salivary gland cancer. So, a really exciting, quick-to-market possibility for our first full registration for darlifarnib. At the same time, we have a combination trial in renal cell carcinoma, where we anticipate the results from that in the second half of 2027.
We also have a combination trial in pancreatic cancer that Molly will share more about, and we could see early results from that in the second half of next year. So, we have a very exciting 2027, particularly for darlifarnib. I will add, very importantly, that we are also well-capitalized and resourced to be able to deliver on the really important milestones we have coming up.
That is great. Yeah, I mean, just seems like there is a lot of stuff going on, a lot of milestones happening over the next 12 months. So, let us dive into KOMZIFTI first. The most recent third quarter numbers looks pretty compelling, especially given that far we are seeing a good number of new patient starts in NPM1 so far. Brian, maybe just help us understand a little bit more around what you are seeing in terms of adoption trends, and how should we think about over the next two or three quarters, the continued growth in new patient starts as well as revenue generation with KOMZIFTI?
Yeah, absolutely. Thanks, David, for the invitation here. It is great to be here. Yeah, so we have seen, as you said, some very robust growth quarter-over-quarter. It is our third full quarter of launch, where we reported $13.9 million in sales, which is about a little over 53% quarter-on-quarter growth. Our new patient starts were at about 150 new patient starts. That was about 35% quarter-on-quarter growth. Our overall total prescriptions were about 420, which is actually about a 65% growth overall. What that is showing us is that, as Jennifer said, all of the growth indicators are kind of going in the right direction. We are seeing kind of extending into new accounts. We grew our number of accounts that are prescribing KOMZIFTI by 40% over the quarter as well.
It is essentially giving us more depth into the market, and also for those accounts we have been treating, but also going into more accounts and getting more breadth going as well. I think this is a testament to the team's execution in a market that, as we know, is competitive, but it gives us an opportunity to really set the foundation for future growth, and we anticipate to see that continuing over the next several quarters as well.
Got it. Great. That is really helpful. Diving into a little bit more, it is interesting that you are already seeing pretty good new patient starts, given the fact that you are only being the third full quarter launch, right, compared to competitors. There are a couple of things I think you mentioned during the call that could drive the adoption trends. One is efficacy, safety, and then also ability to be able to combine, also dose convenience. What has been the most important driver of these adoption for physicians based on your feedback from physicians so far?
Yeah, absolutely. I think that it really, what we have heard is what we have been saying over time, right? It is that the combination of those really is what is setting KOMZIFTI apart. In order to drive uptake and prescriptions from physicians, you need to have efficacy, but you also have to have good tolerability and safety so the patients are able to stay on therapy. The combinability aspect is actually becoming a real pivot for the brand because we need to be able to combine with both concomitant medications like azoles and others without a lot of dose modifications, which makes things simple, but also being able to combine with other therapies like venetoclax, azacitidine, or as we will talk about a bit more about FLT3 as well. The simplicity of once-daily dosing is also useful for patients, and it is simple, I think.
That is something we have heard from not just physicians, but to the pharmacists, the other practitioners, nurses, and things as they treat it. So, it has really given us a strong foundation for us to grow. We think that not just sets us up in the relapse refractory setting, but also gives the opportunity as we move into frontline to really have a differentiated asset that would be able to benefit patients regardless of the combination that they can treat as well.
Combination is very interesting because you did mention that the combination percentage of patients are on combination have increased from 40% to 50% now, right?
How do you envision this number to kind of grow over time? Especially since you're going to have more data coming up at ASH, how do you think that's going to impact physician adoption? Do you think that could translate the data from ASH coming up in December could be able to translate to significant adoption in the next, say, two or three quarters?
Yeah, absolutely. I think that within this space, the NPM1-mutant population, as we entered into this space, we recognized that monotherapy is something that physicians needed to see activity within. But the feedback we heard from so many physicians was, "I really look forward to using this in combination." While our teams are, my commercial team particularly, are going to be promoting according to the label, the physicians start to see the familiarity of how to combine with KOMZIFTI, and that's why we've started to see that growth into that spontaneous use while used in combination. I think that the majority of the combination use has been in combination with venetoclax azacitidine, based on some of the data we published earlier this year in Blood, that demonstrated that the combination was safe, tolerable, and also improved on efficacy.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
